We’re advancing global access to healthcare
Improving worldwide access to healthcare and tackling some of the world’s most devastating and neglected diseases helps give everyone the opportunity to lead a healthy life.
We’re proud that Johnson & Johnson’s actions to expand access to our medicines and focus on addressing diseases that disproportionately impact people in lower- and middle-income countries has ranked the company second in the 2022 Access to Medicine Index.
Our industry-leading performance marks an improvement, up from 3rd in 2021, and is the sixth consecutive time we are featured as a top three performer by the Index.
The Access to Medicine Index
The Access to Medicine Index is a biennial report card that grades the world’s largest pharmaceutical companies on their efforts to advance access to medicines in lower- and middle-income countries. Since the previous ATMI was published, Johnson & Johnson has continued to raise the bar to drive impact, marking milestones, including:
- Supporting the vaccination of more than 200,000 people and strengthening local health systems through a groundbreaking campaign with the Government of Rwanda.
- Launching the Johnson & Johnson Centers for Global Health Discovery, a network of research partnerships around the world aimed at tackling entrenched and emerging health challenges, including TB, antimicrobial resistance (AMR) and dengue.
- Investing $100 million to help found the $1 billion AMR Action Fund, which aims to bring two- to-four new antibiotics to patients by 2030.
- Committing $15 million, via the J&J Foundation, to the Africa Frontline First Catalytic Fund to help build a health workforce across 10 countries in Africa.
